Neeraj Jagdish Agrawal

This inventor holds 21 USPTO granted patents and 15 published patent applications, plus 3 CIPO patents and 7 EPO patents, primarily in Biopharmaceutical Innovations. Top assignees: Amgen Inc., Massachusetts Institute of Technology, Novartis Ag. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Neeraj Jagdish Agrawal. Retrieved from https://idiyas.com/inventor/neeraj-jagdish-agrawal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 15)

% Patents Active = 95.2

CIPO Patents = 3 (Patent Applications = 7)

EPO Patents = 7 (Patent Applications = 12)

Average Co-Inventor Count = 6.1

ph-index = 4

Forward Citations = 43(Granted Patents)

Location History:

Cambridge, MA (US) (2019)
Waltham, MA (US) (2020 - 2022)
Newbury Park, CA (US) (2023)
Thousand Oaks, CA (US) (2017 - 2024)
Natick, MA (US) (2021 - 2024)

Company Filing History:

Massachusetts Institute of Technology

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

Antigen Binding Proteins

Bispecific Antibodies

Gastric Inhibitory Peptide

Interleukin-2 Muteins

Therapeutic Polypeptides

Nucleic Acid Molecules

Protein Viscosity

PAC1 Antibodies

Metabolic Disorders

Binding Proteins

VEGF-A-binding Proteins

Amino Acid Residues

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12637521 - LOW-VISCOSITY ANTIGEN BINDING PROTEINS AND METHODS OF MAKING THEM (2026-05-26),

2. 12570966 - MUTATED PIGGYBAC TRANSPOSASE (2026-03-10),

3. 12516111 - DIRECT SELECTION OF CELLS EXPRESSING HIGH LEVELS OF HETEROMERIC PROTEINS USING GLUTAMINE SYNTHETASE INTRAGENIC COMPLEMENTATION VECTORS (2026-01-06),

4. 12384849 - Bispecific antibodies with cleavable C-terminal charge-paired tags (2025-08-12),

5. 12252540 - Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR) (2025-03-18),

6. 12103979 - N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides (2024-10-01),

7. 11993663 - Low-viscosity antigen binding proteins and methods of making them (2024-05-28),

8. 11976103 - Interleukin-2 muteins for the expansion of T-regulatory cells (2024-05-07),

9. 11891435 - Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof (2024-02-06),

10. 11541103 - Interleukin-21 mutein/ anti-PD-1 antibody conjugates (2023-01-03),

11. 11530274 - Anti-STEAP1 antigen-binding protein (2022-12-20),

12. 11518808 - Anti-PD-1 antibodies and methods of treatment (2022-12-06),

13. 11248043 - Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof (2022-02-15),

14. 11059908 - Low-viscosity antigen binding proteins and methods of making them (2021-07-13),

15. 11046774 - Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists (2021-06-29),

Title: Neeraj Jagdish Agrawal: Innovator in Biotherapeutics

Introduction

Neeraj Jagdish Agrawal, based in Waltham, MA, is a prominent inventor with a remarkable portfolio of 18 patents. His innovative work focuses primarily on biotherapeutics, contributing significantly to advancements in medical science.

Latest Patents

Among his latest patents is the invention of bispecific antibodies with cleavable C-terminal charge-paired tags. This invention details a CH3-containing molecule, which includes a first polypeptide with both a CH3 domain and a negatively charged domain consisting of consecutive negatively charged amino acid residues. It also encompasses a second polypeptide containing a CH3 domain and a positively charged domain of consecutive positively charged amino acid residues. Additionally, this patent outlines methods for conjugating synthetic molecules to a multi-specific antigen binding molecule.

Another significant patent involves nucleic acid molecules encoding binding proteins for the gastric inhibitory peptide receptor (GIPR). This invention provides methods for treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide. Conditions such as type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, and diabetic nephropathy are addressed, with certain embodiments involving administration in conjunction with a GLP-1 receptor agonist.

Career Highlights

Neeraj Agrawal has held notable positions at leading institutions such as Amgen Inc. and the Massachusetts Institute of Technology. His diverse experiences in these reputable companies have shaped his approach to research and innovation.

Collaborations

Throughout his career, Neeraj has collaborated with distinguished professionals, including Zhulun Wang and Ian Nevin Foltz. These partnerships have contributed to the success of his innovative projects and the advancement of biotherapeutic applications.

Conclusion

Neeraj Jagdish Agrawal’s extensive work and inventive patents signify his contributions to the field of biotherapeutics. His focus on developing solutions for complex metabolic diseases highlights his commitment to enhancing healthcare through innovation.

Profile summary based on public USPTO records.